摘要
目的本研究旨在探讨SIRT1基因多态性对血糖控制不佳的2型糖尿病患者接受利拉鲁肽联合二甲双胍治疗临床疗效的影响。方法研究纳入接受2型糖尿病治疗血糖控制不佳患者216例,采用利拉鲁肽联合二甲双胍治疗方案,26周后评价临床疗效,分析患者SIRT1基因多态性与疗效之间的关系。结果216例患者接受26周利拉鲁肽联合二甲双胍治疗后,HbA1c、FPG、2h PG和BMI指标均明显下降,且与治疗前相比差异有统计学意义(P<0.05)。TC/CC型患者HbA1c、FPG、BMI、2h PG各指标比TT型患者下降更为明显,差异有统计学意义(P<0.05)。SIRT1基因多态性分析显示患者Rs12778366位点基因型分布频率均符合哈迪温伯格平衡。另外对145例患者STIR1基因mRNA表达分析发现,TT型患者mRNA表达水平也显著低于TC/CC型患者(P<0.001)。结论利拉鲁肽联合二甲双胍在治疗既往血糖控制不佳的2型糖尿病患者中安全有效,且携带C等位基因的患者疗效更好;SIRT1基因Rs12778366位点可能通过影响SIRT1基因mRNA的表达而影响利拉鲁肽联合二甲双胍的临床疗效。
Objective To investigate the effect of SIRT1 gene polymorphism on the clinical efficacy of liraglutide combined with metformin in type 2 diabetes patients with poor glycemic control.Methods 216 type 2 diabetes patients with poor glycemic control were included.Patients were treated with liraglutide combined with metformin.After 26 weeks treatment,the clinical efficacy was evaluated,and the relationship between SIRT1 gene polymorphism and efficacy was analyzed.Results After 26 weeks of treatment with lialulutide combined with metformin,the indexes of HbA1c,FPG,2H PG and BMI of 216 patients were significantly decreased,and the differences were statistically significant compared with those before treatment(P<0.05).The indexes of HbA1c,FPG,BMI and 2h PG in TC/CC patients decreased more significantly than those in TT patients,and the differences were statistically significant(P<0.05).The polymorphism analysis of SIRT1 gene showed that the genotype distri⁃bution frequency of Rs12778366 was in line with hardy Weinberg equilibrium.In addition,the STIR1 mRNA expression analysis of 145 patients showed that the mRNA expression level of TT patients was also significantly lower than that of TC/CC patients(P<0.001).Conclusions Lilarutide combined with metformin is safe and effective in patients with type 2 diabetes with poor glycemic control,and patients with C allele are more effective.Rs12778366 of SIRT1 gene may affect the clinical efficacy of lylalutide combined with metformin by affecting the mRNA expres⁃sion of SIRT1 gene.
作者
高红红
任丽君
马豪莉
王利
侯会娟
司马盼盼
谢骅
宋瑞捧
GAO Honghong;REN Lijun;MA Haoli;WANG Li;HOU Huijuan;SIMA Panpan;XIE Hua;SONG Ruipeng(Department of Endocrinology,He Nan Sheng Zhi San Yuan,Zhengzhou 450002,China)
出处
《实用医学杂志》
CAS
北大核心
2021年第2期205-209,共5页
The Journal of Practical Medicine
基金
河南省医学科技攻关计划项目(编号:2018020581)。
